These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 28597906)
21. Platelet physiology and thrombosis. Andrews RK; Berndt MC Thromb Res; 2004; 114(5-6):447-53. PubMed ID: 15507277 [TBL] [Abstract][Full Text] [Related]
22. High shear stress attenuates agonist-induced, glycoprotein IIb/IIIa-mediated platelet aggregation when von Willebrand factor binding to glycoprotein Ib/IX is blocked. Iijima K; Murata M; Nakamura K; Kitaguchi T; Handa M; Watanabe K; Fujimura Y; Yoshioka A; Ikeda Y Biochem Biophys Res Commun; 1997 Apr; 233(3):796-800. PubMed ID: 9168936 [TBL] [Abstract][Full Text] [Related]
23. [Thrombocyte receptors: current views and therapeutic options]. Peters RJ; Moons AH; Büller HR Ned Tijdschr Geneeskd; 1999 Sep; 143(39):1952-7. PubMed ID: 10526614 [TBL] [Abstract][Full Text] [Related]
24. Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. De Marco L; Mazzuccato M; Grazia Del Ben M; Budde U; Federici AB; Girolami A; Ruggeri ZM J Clin Invest; 1987 Aug; 80(2):475-82. PubMed ID: 3038958 [TBL] [Abstract][Full Text] [Related]
25. Surface-secreted von Willebrand factor mediates aggregation of ADP-activated platelets at moderate shear stress: facilitated by GPIb but controlled by GPIIb-IIIa. Frojmovic MM; Kasirer-Friede A; Goldsmith HL; Brown EA Thromb Haemost; 1997 Mar; 77(3):568-76. PubMed ID: 9066012 [TBL] [Abstract][Full Text] [Related]
27. The role of the platelet in the pathogenesis of atherothrombosis. Steinhubl SR; Moliterno DJ Am J Cardiovasc Drugs; 2005; 5(6):399-408. PubMed ID: 16259528 [TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies against platelet membrane glycoproteins IIb/IIIa and Ibalpha inhibit platelet dependent thrombin generation by different mechanisms. Thomas S; Metcalfe P; Goodall AH; Gray E Thromb Haemost; 2000 Jul; 84(1):98-103. PubMed ID: 10928478 [TBL] [Abstract][Full Text] [Related]
29. Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa. De Marco L; Mazzucato M; De Roia D; Casonato A; Federici AB; Girolami A; Ruggeri ZM J Clin Invest; 1990 Sep; 86(3):785-92. PubMed ID: 2394830 [TBL] [Abstract][Full Text] [Related]
30. Novel antithrombotic therapeutics targeted against platelet glycoprotein IIb/IIIa. Coutré S; Leung L Annu Rev Med; 1995; 46():257-65. PubMed ID: 7598462 [TBL] [Abstract][Full Text] [Related]
31. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131 [TBL] [Abstract][Full Text] [Related]
32. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101 [TBL] [Abstract][Full Text] [Related]
33. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor. Hoylaerts MF Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916 [TBL] [Abstract][Full Text] [Related]
34. Common variations in platelet glycoproteins: pharmacogenomic implications. Quinn MJ; Topol EJ Pharmacogenomics; 2001 Nov; 2(4):341-52. PubMed ID: 11722284 [TBL] [Abstract][Full Text] [Related]
35. Shear stress-induced binding of von Willebrand factor to platelets. Konstantopoulos K; Chow TW; Turner NA; Hellums JD; Moake JL Biorheology; 1997; 34(1):57-71. PubMed ID: 9176590 [TBL] [Abstract][Full Text] [Related]
36. A new approach to antiplatelet therapy: inhibitor of GPIb/V/IX-vWF interaction. Ikeda Y; Handa M; Murata M; Goto S Haemostasis; 2000; 30 Suppl 3():44-52. PubMed ID: 11182627 [TBL] [Abstract][Full Text] [Related]
37. von Willebrand factor contained in a high purity FVIII concentrate (Fanhdi) binds to platelet glycoproteins and supports platelet adhesion to subendothelium under flow conditions. Rivera J; Escolar G; Casamiquela R; Bravo MI; Jorquera JI; Castillo R; Ordinas A; Vicente V Haematologica; 1999 Jan; 84(1):5-11. PubMed ID: 10091386 [TBL] [Abstract][Full Text] [Related]
38. Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Firbas C; Siller-Matula JM; Jilma B Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1689-701. PubMed ID: 21108551 [TBL] [Abstract][Full Text] [Related]
39. Asialo von Willebrand factor interactions with platelets. Interdependence of glycoproteins Ib and IIb/IIIa for binding and aggregation. Grainick HR; Williams SB; Coller BS J Clin Invest; 1985 Jan; 75(1):19-25. PubMed ID: 2981249 [TBL] [Abstract][Full Text] [Related]
40. Novel antiplatelet drugs in clinical development. Ungerer M; Münch G Thromb Haemost; 2013 Nov; 110(5):868-75. PubMed ID: 24108565 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]